Guardant Health, Inc. (GH)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Helmy Eltoukhy Ph.D. | Co-Founder, Co-CEO & Chairman | 11.63k | -- | 1980 |
| Dr. AmirAli Talasaz Ph.D. | Co-CEO & Director | 11.18k | -- | 1980 |
| Mr. Michael Bell | Chief Financial Officer | 630.99k | -- | 1969 |
| Mr. John G. Saia | Chief Legal Officer & Corporate Secretary | 627.18k | -- | 1973 |
| Dr. Craig Eagle M.D. | Chief Medical Officer | 649.13k | -- | 1967 |
| Mr. Christopher Freeman | Chief Commercial Officer | 630.39k | -- | 1974 |
| Ms. Darya Chudova | Chief Technology Officer | -- | -- | -- |
| Mr. Kumud Kalia | Chief Information Officer | -- | -- | 1966 |
| Ms. Jennifer Higgins | Senior Vice President of Public Affairs | -- | -- | -- |
| Ms. Terilyn Juarez Monroe | Chief People Officer | -- | -- | 1967 |
Guardant Health, Inc.
- Sector:
- Healthcare
- Industry: Diagnostics & Research
- Full Time Employees:
- 1,768
Description
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Corporate Governance
Recent Events
- Mar 22, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 23, 2024S-8: Offering RegistrationsSee Full Filing
- Feb 22, 202410-K: Periodic Financial ReportsSee Full Filing
- Feb 01, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 25, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing